We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Marrone Bio Innovations, Inc. (“Marrone Bio” or the “Company”) (NASDAQ: MBII) in connection with the proposed merger of the Company with Bioceres Solutions Corp. (“Bioceres”) (NASDAQ: BIOX).  Under the terms of the merger agreement, each share of MBI common stock owned will be exchanged at closing for ordinary shares of Bioceres at a fixed ratio of 0.088, representing implied per-share merger consideration of approximately $1.18 based upon Bioceres’s March 17, 2022 closing price of $13.35.

Weiss Law is investigating whether: (i) Marrone Bio’s board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the per-share merger consideration adequately compensates Marrone Bio’s shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.